Literature DB >> 31542060

Melanoma Development: Current Knowledge on Melanoma Pathogenesis.

Liborija Lugović-Mihić1, Diana Ćesić, Petra Vuković, Gaby Novak Bilić, Mirna Šitum, Sanja Špoljar.   

Abstract

The pathogenic features of melanomas include growth and amplification of atypical melanocytes associated with several features (self-sufficiency of growth factors, insensitivity to growth inhibitors, evasion of cellular apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion, and metastasis). These melanoma pathogenic events can be triggered by activating oncogenes or inactivating tumor-suppressor genes by means of molecular mechanisms such as dotted mutations, deletions, and translocations or epigenetic mechanisms such as microRNA expression and promoter methylation. In melanomas, an analysis of the gene aberrations in the genome has led to the discovery of the complex interaction of signaling pathways. Progression of melanomas also involves genetic instability and selective growth of cells with favorable mutations. Additional factors include genetic predisposition, mutagenesis, and suppressed host immune response. Some of the most important signaling pathways involved in the pathogenesis of melanoma are the MAPK, PI3K/PTEN/AKT, and MITF signaling pathways. Obtaining insight into the biology of melanocytes and pathogenesis of melanomas is important for the development of a targeted therapy (such as vemurafenib, dabrafenib, trametinib) as well as the immunotherapy (e.g. pembrolizumab, nivolumab, ipilimumab), which has enabled a substantial breakthrough in the treatment of patients with melanoma.

Entities:  

Mesh:

Year:  2019        PMID: 31542060

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  19 in total

1.  Down-regulated expression of miR-582 predicts poor prognosis and facilitates melanoma progression by targeting FOXC1.

Authors:  Fang Chen; Dapeng Zhang
Journal:  Arch Dermatol Res       Date:  2021-10-10       Impact factor: 3.033

Review 2.  Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy.

Authors:  Yu-Gui Zhang; Jiang-Tao Niu; Hong-Wei Wu; Xin-Lei Si; Shu-Juan Zhang; Dong-Hui Li; Tian-Tian Bian; Yue-Feng Li; Xing-Ke Yan
Journal:  Anal Cell Pathol (Amst)       Date:  2021-06-05       Impact factor: 2.916

3.  Long Noncoding RNA LINC00173 Promotes the Malignancy of Melanoma by Promoting the Expression of IRS4 Through Competitive Binding to microRNA-493.

Authors:  Fan Yang; Pengzhen Lei; Weihui Zeng; Jianwu Gao; Na Wu
Journal:  Cancer Manag Res       Date:  2020-05-05       Impact factor: 3.989

4.  Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.

Authors:  Reinhard Dummer; Simone M Goldinger; Alexandra Valeska Matter; Sara Micaletto; Ursula Urner-Bloch
Journal:  Oncologist       Date:  2020-09-21

Review 5.  Pyroptosis: mechanisms and diseases.

Authors:  Pian Yu; Xu Zhang; Nian Liu; Ling Tang; Cong Peng; Xiang Chen
Journal:  Signal Transduct Target Ther       Date:  2021-03-29

6.  Coexpressed Genes That Promote the Infiltration of M2 Macrophages in Melanoma Can Evaluate the Prognosis and Immunotherapy Outcome.

Authors:  Kexin Yan; Yutao Wang; Yuxiu Lu; Zhangyong Yan
Journal:  J Immunol Res       Date:  2021-03-08       Impact factor: 4.818

Review 7.  Gangliosides as Signaling Regulators in Cancer.

Authors:  Norihiko Sasaki; Masashi Toyoda; Toshiyuki Ishiwata
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

8.  Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma.

Authors:  Corina Daniela Ene; Mircea Tampa; Ilinca Nicolae; Cristina Iulia Mitran; Madalina Irina Mitran; Clara Matei; Ana Caruntu; Constantin Caruntu; Simona Roxana Georgescu
Journal:  J Immunol Res       Date:  2020-08-13       Impact factor: 4.818

9.  A20 promotes melanoma progression via the activation of Akt pathway.

Authors:  Jinyuan Ma; Huina Wang; Sen Guo; Xiuli Yi; Tao Zhao; Yu Liu; Qiong Shi; Tianwen Gao; Chunying Li; Weinan Guo
Journal:  Cell Death Dis       Date:  2020-09-23       Impact factor: 8.469

10.  Low Blue Dose Photodynamic Therapy with Porphyrin-Iron Oxide Nanoparticles Complexes: In Vitro Study on Human Melanoma Cells.

Authors:  Simona Nistorescu; Ana-Maria Udrea; Madalina Andreea Badea; Iulia Lungu; Mihai Boni; Tatiana Tozar; Florian Dumitrache; Valentin-Adrian Maraloiu; Roua Gabriela Popescu; Claudiu Fleaca; Ecaterina Andronescu; Anca Dinischiotu; Angela Staicu; Mihaela Balas
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.